|Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Marks Milestone with Patent Approval|
- LXRP awarded broad-ranging U.S. patent for novel DehydraTECH™ drug delivery system
- Already scientifically proven to increase efficacy of cannabinoids
- IP protection opens myriad business opportunities
Food bioscience company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) just hit another major milestone in the disruption of drug delivery and administration. With 19 international patent applications filed encompassing 44 countries, Lexaria recently announced its reception of a broad-ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients (http://nnw.fm/x4x3C). The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. As the ramifications of this milestone begin to reverberate in the market, Lexaria is continuing to advance all of its other patent applications around the world while leveraging its patent success in the U.S.
Award of the patents come as little surprise, since Lexaria’s DehydraTECH™ technology has been laboratory and market proven to enhance the performance of beneficial compounds in ingestible products. The speed with which the patent was awarded and the breadth of its utilization in other sectors could be viewed as an indication of the importance of the technology. Lexaria’s lipophilic delivery platform, scientifically shown to enhance absorption of orally-ingested cannabinoids, is believed to be applicable across a wide range of different vitamins, drug types and various cannabinoids, dramatically impacting bioabsorption and bioavailability, as well as taste, smell and speed of action. The recently granted U.S. patent solidifies Lexaria’s position as a disruptive force in innovative drug delivery platforms.
In a news release, Chief Executive Officer Chris Bunka stated, “Lexaria has now locked-up the IP for its next-generation drug delivery system. This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world’s first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”
Lexaria’s DehydraTECH™ technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers and can be used with both patented and generic pharmaceutical substances. This breakthrough plays into Lexaria’s long term strategy to partner with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery more predictable, safer and more effective.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer